Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1178]
Discontinued
Reference number: GID-TA10199
As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of avacopan for inducing remission in anti-neutrophil cytoplasmic antibody-associated vasculitis.
Following on from advice received from the company the timelines for this appraisal are currently to be confirmed. This is because the company have decided to withdraw the avacopan application for a Conditional Marketing Authorisation (CMA) with the European Medicines Agency based on Phase II data, in light of the upcoming availability of data from the pivotal phase III trial Advocate.
Therefore, NICE will continue to liaise with the company regarding the anticipated regulatory timings of avacopan in this indication and further information regarding the scheduling of this appraisal will be available in due course.